Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
L CrinòM Tonato

Abstract

The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin in preclinical models suggested synergy between the two drugs. The aim of the study was to evaluate the clinical efficacy and toxicity of the cisplatin-gemcitabine combination in advanced NSCLC. Forty-eight consecutive previously untreated NSCLC patients entered the trial from January to June 1994. The median age was 60 years (range, 37 to 70) and performance status (PS) was 0 or 1; 22 patients had unresectable stage III disease (21 stage IIIB and one stage IIIA) and 26 had stage IV disease. Gemcitabine 1 g/m2 was administered weekly (days 1, 8, and 15) followed by a 1-week rest and cisplatin 100 mg/m2 on day 2 of each 28-day cycle. Survival and response were determined in accordance with the intention-to-treat principle in all enrolled patients. Of 48 assessable patients, one (stage IV) had a complete response (CR) and 25 achieved a partial response (PR). The overall response rate was 54% (95% confidence interval [CI], 40% to 68%). Thrombocytopenia was the main side effect, with 52% of patients experiencing grade III to IV toxicity, which was usually short-li...Continue Reading

Citations

Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoH Cortes-Funes
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ComellaG Comella
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F DeVoreL L Miller
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R KroepG J Peters
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FrasciG Comella
Aug 22, 2002·British Journal of Cancer·A K NowakB W S Robinson
Feb 1, 2006·Expert Review of Anticancer Therapy·Antonio Saha, Robin Rudd
Feb 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jong-Sung ParkHyo-Jin Kim
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Apr 27, 1999·Cancer Nursing·M Barton-Burke
Feb 17, 2000·Australian and New Zealand Journal of Medicine·J R DavisJ R Zalcberg
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D PectasidesA Athanassiou
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B F El-RayesP A Philip
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A B SandlerL H Einhorn
Nov 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·Chai-Hooi Leow, Chong-Kin Liam
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen G DiversFrancisco Robert
Feb 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vassilis GeorgouliasDora Chatzidaki
Jun 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Nam-Su LeeHee-Sook Park
Apr 30, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Tian-Tian SunJing-Yuan Fang
Nov 2, 2013·Oncology Letters·Faruk TasSenem Karabulut
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L CrinòM Tonato
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F CardenalR Rosell
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucio TrodellaNuma Cellini
Feb 15, 2001·Japanese Journal of Cancer Research : Gann·M MatsumotoT Yoshioka
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart C KuenenGiuseppe Giaccone
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
G CarteiG Tabaro
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A M MosconiM Tonato
© 2022 Meta ULC. All rights reserved